Biologics DNA methylation Epigénétiques MALT MARKER Ulcerative colitis Inflammatory bowel disease Rituximab Dysbiose Drug Tuberculosis IL12 Over 80s Crohn’s disease Endoscopic treatment MICROBIOTA Patient-reported outcome Eligibility Effectiveness Acceptability Bacteria Dysbiosis Vedolizumab Gene expression Bactéries Disability Gènes Colon cancer Colon Eradication T1118 translocation Kidney diseases Maintenance therapy Immunosuppressant Primary sclerosing cholangitis COLON-CANCER Gene methylation Alkylating agents Stricture Microbiote Fecal microbiota Monitoring Original Article Clinical Biomarker Thérapie ciblée Inhibitor Tailored therapy PCR Surgery Algorithm Clinical trial Epigenetics Contraindication Intestinal crypts Heart disease risk factors Inflammatory bowel diseases Résistance Anti-TNF HIV Neoadjuvant chemotherapy Ustekinumab Microbiota Colonic epithelial primary cells Clinical guidelines Survival Consensus Screening 18 FDG-PET/CT RISK Méthylation Methylation MORTALITY Resistance IL23 Colectomy Parvimonas micra Colorectal cancer IBD Cost effectiveness Disease Progression Genes Disease progression Cell adhesion Safety Venous thromboembolism Inclusion Cancer DNA METHYLATION Small molecules Upper gastrointestinal tract Immune cells Rituximab plus chlorambucil Crohn's disease Colorectal cancer Colibactin and lipids Anti-TNF agents Inflammatory Bowel Diseases Patients experience Helicobacter pylori CARCINOGENESIS Therapeutics